GNRO — Geneuro SA Share Price
0.000.00%
Last trade - 00:00- €36.71m
- €36.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -176.29% | ||
| Return on Equity | -1250.96% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 7.46 | n/a | n/a | n/a | n/a | 20 | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
Directors
- Jesus Martin-Garcia CHM (58)
- Miguel Payro CFO (58)
- Herve Perron CSO (62)
- Jean-francois Arrighi OTH (55)
- David Leppert OTH (63)
- Hedi Brahim IND (40)
- Giacomo Di Nepi IND (68)
- Michel Dubois IND (78)
- Eric Falcand IND (59)
- Gordon Francis IND (71)
- Christophe Guichard IND (51)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- February 6th, 2006
- Public Since
- April 15th, 2016
- No. of Employees
- 20
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 24,889,423
- Address
- 3, Chemin du Pre-Fleuri, PLAN-LES-OUATES, 1228
- Web
- https://www.geneuro.com/
- Phone
- +41 225524800
- Auditors
- PricewaterhouseCoopers SA
Upcoming Events for GNRO
Q1 2024 Geneuro SA Earnings Release
Geneuro SA Annual Shareholders Meeting
Q2 2024 Geneuro SA Earnings Release
Similar to GNRO
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
What is the Geneuro SA share price?
As of Today at 19:09 UTC, shares in Geneuro SA are trading at €1.48. This share price information is delayed by 15 minutes.
How has the Geneuro SA share price performed this year?
Shares in Geneuro SA last closed at €1.48 and the price had moved by -20.27% over the past 365 days. In terms of relative price strength the Geneuro SA share price has underperformed the FTSE Global All Cap Index by -26.46% over the past year.
What are the analyst and broker recommendations for Geneuro SA?
The overall consensus recommendation for Geneuro SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Geneuro SA dividend yield?
Geneuro SA does not currently pay a dividend.
Does Geneuro SA pay a dividend?
Geneuro SA does not currently pay a dividend.
When does Geneuro SA next pay dividends?
Geneuro SA does not currently pay a dividend.
How do I buy Geneuro SA shares?
To buy shares in Geneuro SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Geneuro SA?
As of the previous close price of €1.48, shares in Geneuro SA had a market capitalisation of €36.71m.
Where are Geneuro SA shares listed?
Here are the trading details for Geneuro SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: GNRO
What kind of share is Geneuro SA?
Based on an overall assessment of its quality, value and momentum Geneuro SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Geneuro SA share price forecast for 2024?
The analyst consensus target price for shares in Geneuro SA is €7.10. That is 381.36% above the last closing price of €1.48.
Analysts covering Geneuro SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.32 for the next financial year.
What is the trend in the Geneuro SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Geneuro SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +14.08%.
As of the last closing price of €1.48, shares in Geneuro SA were trading +11.67% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Geneuro SA PE Ratio?
The Geneuro SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €1.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Geneuro SA?
Geneuro SA's management team is headed by:
- Jesus Martin-Garcia - CHM
- Miguel Payro - CFO
- Herve Perron - CSO
- Jean-francois Arrighi - OTH
- David Leppert - OTH
- Hedi Brahim - IND
- Giacomo Di Nepi - IND
- Michel Dubois - IND
- Eric Falcand - IND
- Gordon Francis - IND
- Christophe Guichard - IND